An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Harari, Alexandre; Bart, Pierre-Alexandre; Stöhr, Wolfgang; Tapia, Gonzalo; Garcia, Miguel; Medjitna-Rais, Emmanuelle; Burnet, Séverine; Cellerai, Cristina; Erlwein, Otto; Barber, Tristan; Moog, Christiane; Liljestrom, Peter; Wagner, Ralf; Wolf, Hans; Kraehenbuhl, Jean-Pierre; Esteban, Mariano; Heeney, Jonathan; Frachette, Marie-Joelle; Tartaglia, James; McCormack, Sheena; Babiker, Abdel; Weber, Jonathan; Pantaleo, Giuseppe

doi:10.1084/jem.20071331

Public

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Shared by NobleBlocks on Jan 21, 2008 • 12:00 AM UTC

Authors:

Alexandre Harari

Pierre-Alexandre Bart

Wolfgang Stöhr

Abstract

The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C is...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!